J. B. Chemicals & Pharmaceuticals Limited (JBCPL), one of the fastest-growing pharmaceutical companies in India, announced its financial results for the fourth quarter and fiscal year ended 31st March 2021. The company registered 101% growth in PAT at Rs at Rs101cr as compared to Rs50cr for the fourth quarter ended 31st March 2021.

The company recorded revenue of Rs 528crore as compared to Rs 444 crore, registering a growth of 19% over the corresponding quarter ended 31st March 2020.EBITDA (Earnings Before Interest Depreciation and Taxes) increased by 35% to Rs 124 crore as compared to Rs 92 croe. EBITDA margin for the quarter was at 23% as compared to 21%.

Commenting on financial results, Nikhil Chopra, CEO and Whole-time Director, JBCPL said, “Our financial performance for FY21 has been encouraging in one of the most challenging periods in recent history. We are pleased with the strength showcased by all our business units – with the India business continuing to record market-beating growth for the year - backed by a new consolidated go-to-market strategy with therapy diversification plans and strong transformation levers to sustain growth.”

“Our international formulations business has performed well and shows great promise with a focused growth strategy for our key markets, aided by new launches. Overall, our plans of strengthening R&D capabilities to support our medium to long-term growth opportunities and various cost efficiency initiatives instituted over the last year places us well to enhance value for all our key stakeholders,” Chopra added.